Cargando…

Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation

Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low water solubility, making its application for the treatment of ocular inflammation difficult. To overcome this drawback, biodegradable nanoparticles incorporating Licochalcone-A have been developed. Addi...

Descripción completa

Detalles Bibliográficos
Autores principales: Galindo, Ruth, Sánchez-López, Elena, Gómara, María José, Espina, Marta, Ettcheto, Miren, Cano, Amanda, Haro, Isabel, Camins, Antoni, García, María Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874979/
https://www.ncbi.nlm.nih.gov/pubmed/35214019
http://dx.doi.org/10.3390/pharmaceutics14020285
_version_ 1784657815731699712
author Galindo, Ruth
Sánchez-López, Elena
Gómara, María José
Espina, Marta
Ettcheto, Miren
Cano, Amanda
Haro, Isabel
Camins, Antoni
García, María Luisa
author_facet Galindo, Ruth
Sánchez-López, Elena
Gómara, María José
Espina, Marta
Ettcheto, Miren
Cano, Amanda
Haro, Isabel
Camins, Antoni
García, María Luisa
author_sort Galindo, Ruth
collection PubMed
description Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low water solubility, making its application for the treatment of ocular inflammation difficult. To overcome this drawback, biodegradable nanoparticles incorporating Licochalcone-A have been developed. Additionally, to avoid fast clearance and increase cellular internalization into the ocular tissues, PLGA nanoparticles have been functionalized using PEG and cell penetrating peptides (Tet-1 and B6). To optimize the formulations, a factorial design was carried out and short-term stability of the nanoparticles was studied. Moreover, morphology was also observed by transmission electron microcopy and in vitro drug release was carried out. Ocular tolerance of the formulations was ensured in vitro and in vivo and anti-inflammatory therapeutic efficacy was also assessed. Surface functionalized nanoparticles loading Licochalcone-A were developed with an average size below 200 nm, a positive surface charge, and a monodisperse population. The formulations were non-irritant and showed a prolonged Licochalcone-A release. Despite the fact that both Licochalcone-A Tet-1 and B6 functionalized nanoparticles demonstrated to be suitable for the treatment of ocular inflammation, B6 targeted nanoparticles provided greater therapeutic efficacy in in vivo assays.
format Online
Article
Text
id pubmed-8874979
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88749792022-02-26 Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation Galindo, Ruth Sánchez-López, Elena Gómara, María José Espina, Marta Ettcheto, Miren Cano, Amanda Haro, Isabel Camins, Antoni García, María Luisa Pharmaceutics Article Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low water solubility, making its application for the treatment of ocular inflammation difficult. To overcome this drawback, biodegradable nanoparticles incorporating Licochalcone-A have been developed. Additionally, to avoid fast clearance and increase cellular internalization into the ocular tissues, PLGA nanoparticles have been functionalized using PEG and cell penetrating peptides (Tet-1 and B6). To optimize the formulations, a factorial design was carried out and short-term stability of the nanoparticles was studied. Moreover, morphology was also observed by transmission electron microcopy and in vitro drug release was carried out. Ocular tolerance of the formulations was ensured in vitro and in vivo and anti-inflammatory therapeutic efficacy was also assessed. Surface functionalized nanoparticles loading Licochalcone-A were developed with an average size below 200 nm, a positive surface charge, and a monodisperse population. The formulations were non-irritant and showed a prolonged Licochalcone-A release. Despite the fact that both Licochalcone-A Tet-1 and B6 functionalized nanoparticles demonstrated to be suitable for the treatment of ocular inflammation, B6 targeted nanoparticles provided greater therapeutic efficacy in in vivo assays. MDPI 2022-01-26 /pmc/articles/PMC8874979/ /pubmed/35214019 http://dx.doi.org/10.3390/pharmaceutics14020285 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Galindo, Ruth
Sánchez-López, Elena
Gómara, María José
Espina, Marta
Ettcheto, Miren
Cano, Amanda
Haro, Isabel
Camins, Antoni
García, María Luisa
Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
title Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
title_full Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
title_fullStr Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
title_full_unstemmed Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
title_short Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
title_sort development of peptide targeted plga-pegylated nanoparticles loading licochalcone-a for ocular inflammation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874979/
https://www.ncbi.nlm.nih.gov/pubmed/35214019
http://dx.doi.org/10.3390/pharmaceutics14020285
work_keys_str_mv AT galindoruth developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation
AT sanchezlopezelena developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation
AT gomaramariajose developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation
AT espinamarta developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation
AT ettchetomiren developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation
AT canoamanda developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation
AT haroisabel developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation
AT caminsantoni developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation
AT garciamarialuisa developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation